Bank of America Boosts Johnson & Johnson (NYSE:JNJ) Price Target to $263.00

Johnson & Johnson (NYSE:JNJ) had its price target lifted by analysts at Bank of America from $254.00 to $263.00 in a report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s target price suggests a potential upside of 2.59% from the stock’s previous close.

Several other research firms have also recently issued reports on JNJ. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $283.00 to $284.00 and gave the company an “overweight” rating in a report on Wednesday. Daiwa Securities Group boosted their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a report on Thursday, April 16th. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $258.13.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $2.74 during mid-day trading on Friday, hitting $256.36. 3,506,841 shares of the company were exchanged, compared to its average volume of 8,409,417. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market cap of $617.12 billion, a price-to-earnings ratio of 29.64, a price-to-earnings-growth ratio of 2.58 and a beta of 0.24. The stock has a 50 day simple moving average of $236.47 and a 200-day simple moving average of $232.88. Johnson & Johnson has a 1-year low of $154.80 and a 1-year high of $269.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently bought and sold shares of the business. Greenberg Financial Group bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $954,000. World Investment Advisors boosted its stake in shares of Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares in the last quarter. Coldstream Capital Management Inc. raised its holdings in Johnson & Johnson by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock worth $17,738,000 after purchasing an additional 8,533 shares in the last quarter. Benchmark Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $554,000. Finally, Sagespring Wealth Partners LLC grew its position in shares of Johnson & Johnson by 6.2% in the 4th quarter. Sagespring Wealth Partners LLC now owns 45,222 shares of the company’s stock worth $9,359,000 after buying an additional 2,660 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is backing the RELIEVE-HFrEF clinical trial for the V-Wave Ventura heart failure device, which adds another potential growth opportunity in its medtech portfolio if the study shows strong results. JNJ Backs New Heart Failure Device Trial: What Investors Should Watch
• Positive Sentiment: Analyst and media coverage continues to highlight JNJ as a defensive dividend name with strong earnings power, and several outlets say the company still screens well for income investors and could benefit from a “buy the dip” mindset. 3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026
• Positive Sentiment: Commentary from Jim Cramer was upbeat, saying Johnson & Johnson should have “lots of good news” ahead from its blockbuster drugs, which can support sentiment around the stock’s pharma franchise. Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”
• Neutral Sentiment: Coverage ahead of JNJ’s upcoming Q2 earnings is focusing on whether it can beat estimates again, but this is still just a preview rather than a fresh fundamental update. Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
• Neutral Sentiment: A comparison piece versus AbbVie is drawing attention to JNJ’s different strategy, but it does not point to a specific catalyst for the shares today. Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
• Negative Sentiment: The stock has also been pressured by recent session-to-session declines, suggesting some investors are taking profits or waiting for the next earnings update before adding exposure. Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.